Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial - Scorecard - MDSpire

Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial

  • By

  • Chloe Stanley

  • Ritwika Mallik

  • Nausheen Hamid

  • Friedrich C. Jassil

  • Victoria Reuven

  • Tapiwa Ruwona

  • Samuel J. Dicken

  • Sulmaaz Qamar

  • Benjamin Norton

  • Helen Kingett

  • Andrea Pucci

  • Cormac Magee

  • David Boniface

  • Rachel L. Batterham

  • Kalpana Devalia

  • Jessica Mok

  • Mohamed Elkalaawy

  • John Loy

  • Andrew Jenkinson

  • Haris Markakis

  • Marco Adamo

  • Alanna Brown

  • Janine Makaronidis

  • May 22, 2026

  • 0 min

Share

Clinical Scorecard: Comparison of Semaglutide and Placebo in Patients with Inadequate Weight Loss Following Bariatric Surgery: A Randomized, Double-Blind, Placebo-Controlled Study

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target Population
Care Setting

Key Highlights

  • remove

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Adults with obesity or overweight and at least one weight-related comorbidity.

          Semaglutide 2.4 mg has shown superior efficacy in weight management compared to liraglutide.

          Clinical Best Practices

          • remove

          Related Resources & Content

          Original Source(s)

          Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial

          • by Chloe Stanley, Ritwika Mallik, Nausheen Hamid, Friedrich C. Jassil, Victoria Reuven, Tapiwa Ruwona, Samuel J. Dicken, Sulmaaz Qamar, Benjamin Norton, Helen Kingett, Andrea Pucci, Cormac Magee, David Boniface, Rachel L. Batterham, Kalpana Devalia, Jessica Mok, Mohamed Elkalaawy, John Loy, Andrew Jenkinson, Haris Markakis, Marco Adamo, Alanna Brown, Janine Makaronidis

          • May 22, 2026

          Related Content

          Opposing gastric and jejunal regulation of CELA2A in obesity and after Roux-en-Y gastric bypass suggests a role in gastrointestinal metabolic signaling

          The role of metabolic reprogramming in oocyte development: research progress and prospects

          Dietary patterns, metabolic pathways and metainflammation in hidradenitis suppurativa: a systematic review